Gilead to expand US manufacturing with $11B investment in new and upgraded facilities

Gilead Sciences has announced a multi-year, multi-billion-dollar investment plan designed to strengthen its U.S.-based manufacturing and research infrastructure. 

The initiative includes $11 billion in new capital and operational expenditures, building on a previously announced $21 billion spend through 2030. Combined, the company projects these efforts will generate $43 billion in economic impact over the next five years.

A key component of the investment is the construction of three advanced manufacturing facilities and the upgrade of three existing sites. Gilead stated that these expansions are intended to boost the company’s capacity to produce complex therapeutics domestically, with an emphasis on high-value biologics and personalized medicines. The planned upgrades will also support clinical and commercial production of the company’s pipeline candidates.

Of the $11 billion investment, $4 billion is allocated for capital projects — including new laboratories and specialized equipment for manufacturing. Another $5 billion will go toward expanding operations and technology infrastructure at Gilead’s R&D sites.

The final $2 billion is focused on digital and advanced engineering initiatives, including the deployment of automation and IT systems that support modern pharmaceutical production.

Gilead has not yet disclosed the locations of the new or upgraded facilities, but the company said site selection will consider factors such as access to skilled labor, proximity to research institutions, and infrastructure readiness.

The company’s current U.S. manufacturing footprint includes sites in California, Maryland, and North Carolina, with facilities dedicated to both large- and small-molecule production, as well as cell and gene therapies.

This move aligns with broader industry efforts to localize drug manufacturing amid rising global supply chain risks and federal calls for greater domestic production of essential medicines. Gilead’s investments are expected to support improved supply chain resilience and reduce dependency on offshore production, particularly for advanced therapeutics.

The expansion is also expected to generate 800 direct jobs and support more than 2,200 indirect roles by 2028. According to Gilead, this effort continues the company’s longstanding commitment to investing in U.S.-based infrastructure, which has included $15 billion in domestic spending over the past decade.

Gilead, headquartered in Foster City, California, is a global biopharmaceutical company focused on antiviral and oncology therapies. In recent years, it has expanded its presence in the cell and gene therapy space through acquisitions such as Kite Pharma and Immunomedics. The company reported $27 billion in 2024 revenue and has signaled ongoing investment in pipeline development and advanced manufacturing capabilities.

The company’s expansion strategy places it among several pharmaceutical companies that are increasing U.S. production capacity in response to regulatory and market pressures.